Annexon (ANNX) vs Avalo Therapeutics (AVTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Annexon (ANNX) has outperformed Avalo Therapeutics (AVTX) over the past year, gaining 27.0% versus a loss of 5.6%. Over five years, ANNX leads with a -81.8% price change compared with -99.8% for AVTX. Annexon is the larger company by market cap ($758.3 million vs $720.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANNX | AVTX |
|---|---|---|
| Share price | $4.00 | $13.43 |
| Market cap | $758.32M | $720.25M |
| 1-day change | -0.25% | -1.10% |
| YTD return | -20.32% | -26.05% |
| 1-year return | +26.98% | -5.56% |
| 5-year return | -81.82% | -99.79% |
| EPS (TTM) | $-1.12 | $-4.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.18 | $24.27 |
| 52-week low | $2.54 | $12.51 |
| Distance from 52-week high | -44.29% | -44.66% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +285.75% | +228.22% |
| Average volume | 3.11M | 925.93K |
| Shares outstanding | 189.58M | 53.63M |
| Employees | 92 | 33 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANNX has outperformed AVTX by 32.5 percentage points over the past year.
- The two companies sit in different sectors: Annexon in Healthcare and Avalo Therapeutics in Health Care.
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Healthcare · Biotechnology · 92 employees
About Avalo Therapeutics
AVTX stock →Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
ANNX vs AVTX FAQ
Which is bigger, Annexon or Avalo Therapeutics?
Annexon (ANNX) is larger, with a market capitalization of $758.32M compared with $720.25M for Avalo Therapeutics (AVTX).
Which stock has performed better over the past year, ANNX or AVTX?
ANNX returned +26.98% over the past 12 months, compared with -5.56% for AVTX (price return, excluding dividends). Past performance does not predict future results.
Are Annexon and Avalo Therapeutics in the same industry?
No. Annexon is in the Healthcare sector, while Avalo Therapeutics is in Health Care.